anurajms/meta_analysis huggingface dataset:
MESH terms:
Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease
1. Administration, Oral; 2. Aminopyridines [*administration & dosage, adverse effects]; 3. Benzamides [*administration & dosage, adverse effects]; 4. Cyclohexanecarboxylic Acids [*administration & dosage, adverse effects]; 5. Cyclopropanes [administration & dosage, adverse effects]; 6. Diarrhea [chemically induced]; 7. Disease Progression; 8. Forced Expiratory Volume [drug effects]; 9. Nitriles [*administration & dosage, adverse effects]; 10. Peak Expiratory Flow Rate [drug effects]; 11. Phosphodiesterase 4 Inhibitors [*administration & dosage, adverse effects]; 12. Pulmonary Disease, Chronic Obstructive [*drug therapy, mortality]; 13. Quality of Life; 14. Randomized Controlled Trials as Topic; 15. Thiazoles [*administration & dosage, adverse effects]; 16. Vital Capacity [drug effects];
MESH terms:
Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD)
1. *Exercise; 2. Pulmonary Disease, Chronic Obstructive [*rehabilitation]; 3. Randomized Controlled Trials as Topic; 4. Telerehabilitation;
MESH terms:
Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea
1. Bias; 2. Cognitive Behavioral Therapy [*methods]; 3. Continuous Positive Airway Pressure [instrumentation, *statistics & numerical data]; 4. Disorders of Excessive Somnolence [epidemiology]; 5. Motivation; 6. Patient Compliance [*statistics & numerical data]; 7. Patient Education as Topic [*methods]; 8. Randomized Controlled Trials as Topic; 9. Reinforcement, Psychology; 10. Sleep Apnea, Obstructive [psychology, *therapy]; 11. Time Factors;
MESH terms:
Breathing exercises for adults with asthma
1. *Yoga; 2. Asthma [physiopathology, *rehabilitation]; 3. Breathing Exercises [*methods]; 4. Disease Progression; 5. Health Education; 6. Hyperventilation; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Respiratory Function Tests;
MESH terms:
Oxygen therapy in the pre‐hospital setting for acute exacerbations of chronic obstructive pulmonary disease
1. *Oxygen Inhalation Therapy; 2. Disease Progression; 3. Dyspnea [drug therapy]; 4. Noninvasive Ventilation; 5. Pulmonary Disease, Chronic Obstructive [*therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Pressure modification or humidification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea
1. *Continuous Positive Airway Pressure [methods]; 2. *Humidifiers; 3. Outcome Assessment, Health Care; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Sleep Apnea, Obstructive [*therapy];
MESH terms:
Pharmacological agents for adults with acute respiratory distress syndrome
1. Adrenal Cortex Hormones [therapeutic use]; 2. Neuromuscular Blocking Agents; 3. Pulmonary Surfactants [therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. *Respiration, Artificial; 6. Respiratory Distress Syndrome [*drug therapy, *mortality];
MESH terms:
Positional therapy for obstructive sleep apnoea
1. *Continuous Positive Airway Pressure; 2. *Supine Position; 3. Outcome Assessment, Health Care; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Sleep Apnea, Obstructive [*therapy];
MESH terms:
Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
1. Adrenergic beta‐2 Receptor Agonists [*administration & dosage, adverse effects]; 2. Cause of Death; 3. Cross‐Over Studies; 4. Disease Progression; 5. Drug Administration Schedule; 6. Drug Combinations; 7. Muscarinic Antagonists [*administration & dosage, adverse effects]; 8. Nebulizers and Vaporizers; 9. Placebos [administration & dosage]; 10. Pulmonary Disease, Chronic Obstructive [*drug therapy, mortality]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic;
MESH terms:
Print‐based self‐help interventions for smoking cessation
1. Behavior Therapy; 2. Chewing Gum; 3. Nicotine [analogs & derivatives, therapeutic use]; 4. Pamphlets; 5. Patient Education as Topic; 6. Polymethacrylic Acids [therapeutic use]; 7. Polyvinyls [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Self Care [*methods]; 10. Smoking Cessation [*methods]; 11. *Smoking Prevention; 12. Temperance [statistics & numerical data]; 13. Tobacco Use Cessation Devices;
MESH terms:
Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)
1. Adrenergic beta-2 Receptor Agonists [*therapeutic use]; 2. Bronchodilator Agents [therapeutic use]; 3. Disease Progression; 4. Drug Therapy, Combination [methods]; 5. Dyspnea [drug therapy]; 6. Forced Expiratory Volume; 7. Formoterol Fumarate [therapeutic use]; 8. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Tropanes [*therapeutic use];
MESH terms:
Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with chronic obstructive pulmonary disease
1. Attention; 2. Breathing Exercises [methods]; 3. Dyspnea [rehabilitation, therapy]; 4. Meditation [methods]; 5. Mind-Body Therapies [*methods]; 6. Pulmonary Disease, Chronic Obstructive [rehabilitation, *therapy]; 7. Quality of Life; 8. Walking;
MESH terms:
Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*administration & dosage]; 3. Adrenergic beta-2 Receptor Agonists [*administration & dosage]; 4. Androstadienes [administration & dosage]; 5. Benzyl Alcohols [administration & dosage]; 6. Chlorobenzenes [administration & dosage]; 7. Drug Administration Schedule; 8. Forced Expiratory Volume; 9. Muscarinic Antagonists [*administration & dosage]; 10. Pulmonary Disease, Chronic Obstructive [drug therapy]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic;
MESH terms:
Enhancing partner support to improve smoking cessation
1. *Family; 2. *Friends; 3. *Social Support; 4. *Spouses; 5. Randomized Controlled Trials as Topic; 6. Smoking Cessation [*methods, psychology, statistics & numerical data]; 7. Time Factors;
MESH terms:
Nicotine replacement therapy versus control for smoking cessation
1. Administration, Cutaneous; 2. Administration, Inhalation; 3. Chewing Gum; 4. Nicotine [administration & dosage]; 5. Nicotinic Agonists [administration & dosage]; 6. Randomized Controlled Trials as Topic; 7. Smoking Cessation [*methods, statistics & numerical data]; 8. Smoking Prevention [*methods, statistics & numerical data]; 9. Tablets; 10. Time Factors; 11. *Tobacco Use Cessation Devices;
MESH terms:
Self‐management for bronchiectasis
1. *Self‐Management [economics]; 2. Bronchiectasis [*therapy]; 3. Disease Progression; 4. Forced Expiratory Volume; 5. Hospitalization; 6. Patient Education as Topic; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Self Efficacy;
MESH terms:
Family and carer smoking control programmes for reducing children's exposure to environmental tobacco smoke
1. Age Factors; 2. *Caregivers; 3. Controlled Clinical Trials as Topic; 4. Cotinine [urine]; 5. Counseling; 6. Environmental Exposure [prevention & control]; 7. *Family; 8. Smoking Cessation; 9. *Smoking Prevention; 10. Tobacco Smoke Pollution [*prevention & control];
MESH terms:
Singing for adults with chronic obstructive pulmonary disease
1. *Quality of Life; 2. Dyspnea [therapy]; 3. Pulmonary Disease, Chronic Obstructive [*therapy]; 4. Singing [*physiology]; 5. Time Factors;
MESH terms:
Nursing interventions for smoking cessation
1. *Counseling; 2. *Practice Patterns, Nurses'; 3. *Smoking Prevention; 4. Randomized Controlled Trials as Topic; 5. Smoking Cessation [*statistics & numerical data];
MESH terms:
Invasive versus non‐invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders
1. *Noninvasive Ventilation; 2. *Respiration, Artificial; 3. Acute Disease; 4. Neuromuscular Diseases [*complications]; 5. Respiratory Insufficiency [etiology, *therapy]; 6. Thoracic Wall [*abnormalities];
MESH terms:
Inhaled magnesium sulfate in the treatment of acute asthma
1. Acute Disease; 2. Administration, Inhalation; 3. Adrenergic beta‐Agonists [*administration & dosage, adverse effects]; 4. Anti‐Asthmatic Agents [*administration & dosage, adverse effects]; 5. Asthma [*drug therapy]; 6. Bronchodilator Agents [administration & dosage]; 7. Disease Progression; 8. Drug Therapy, Combination [methods]; 9. Hospitalization [statistics & numerical data]; 10. Ipratropium [administration & dosage]; 11. Magnesium Sulfate [*administration & dosage, adverse effects]; 12. Patient Readmission [statistics & numerical data]; 13. Randomized Controlled Trials as Topic; 14. Respiratory Function Tests;
MESH terms:
Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants
1. *Mesenchymal Stem Cell Transplantation; 2. Bronchopulmonary Dysplasia [prevention & control, *therapy]; 3. Infant, Premature;
MESH terms:
Neurally adjusted ventilatory assist compared to other forms of triggered ventilation for neonatal respiratory support
1. Bronchopulmonary Dysplasia [prevention & control]; 2. Cerebral Intraventricular Hemorrhage [etiology]; 3. Interactive Ventilatory Support [adverse effects, *methods, mortality]; 4. Leukomalacia, Periventricular [etiology]; 5. Respiratory Mechanics [physiology];
MESH terms:
Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates
1. *Infant, Very Low Birth Weight; 2. *Respiration, Artificial; 3. Administration, Inhalation; 4. Anti‐Inflammatory Agents [*administration & dosage, adverse effects]; 5. Beclomethasone [administration & dosage]; 6. Bronchopulmonary Dysplasia [*prevention & control]; 7. Budesonide [administration & dosage]; 8. Chronic Disease; 9. Dexamethasone [administration & dosage]; 10. Infant, Premature; 11. Randomized Controlled Trials as Topic; 12. Respiratory System Agents [administration & dosage, adverse effects]; 13. Steroids [administration & dosage, adverse effects];
MESH terms:
Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants
1. *Infant, Very Low Birth Weight; 2. *Respiration, Artificial; 3. Administration, Inhalation; 4. Beclomethasone [administration & dosage]; 5. Bronchopulmonary Dysplasia [*drug therapy, mortality]; 6. Chronic Disease; 7. Dexamethasone [administration & dosage]; 8. Glucocorticoids [*administration & dosage]; 9. Infant, Premature; 10. Randomized Controlled Trials as Topic; 11. Respiratory System Agents [administration & dosage];
MESH terms:
Shared decision‐making for people with asthma
1. *Clinical Decision‐Making; 2. *Decision Making; 3. *Patient Participation; 4. Asthma [*drug therapy]; 5. Disease Progression; 6. Medication Adherence; 7. Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis
1. *Positive‐Pressure Respiration; 2. *Quality of Life; 3. Bronchiectasis [complications, *therapy]; 4. Cough [therapy]; 5. Disease Progression; 6. Hospitalization [statistics & numerical data]; 7. Randomized Controlled Trials as Topic; 8. Respiratory Therapy [*methods]; 9. Sputum [metabolism];
MESH terms:
Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
1. *Eosinophils; 2. Adrenal Cortex Hormones [therapeutic use]; 3. Anti‐Asthmatic Agents [*therapeutic use]; 4. Asthma [*drug therapy, pathology]; 5. Disease Progression; 6. Leukocyte Count; 7. Randomized Controlled Trials as Topic; 8. Sputum [*cytology];
MESH terms:
Culture‐specific programs for children and adults from minority groups who have asthma
1. *Minority Groups; 2. Asthma [ethnology, *therapy]; 3. Culturally Competent Care [*organization & administration]; 4. Disease Progression; 5. Patient Education as Topic [*methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)
1. Acute Lung Injury [*drug therapy, mortality]; 2. Aerosols; 3. Anti‐Inflammatory Agents [*administration & dosage]; 4. Epoprostenol [*administration & dosage]; 5. Respiratory Distress Syndrome [*drug therapy, mortality]; 6. Vasodilator Agents [*administration & dosage];
MESH terms:
Self‐management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease
1. Anti-Bacterial Agents [therapeutic use]; 2. Cause of Death; 3. *Disease Progression; 4. Dyspnea [diagnosis, epidemiology]; 5. Hospitalization [statistics & numerical data]; 6. Patient Compliance [statistics & numerical data]; 7. Pulmonary Disease, Chronic Obstructive [drug therapy, mortality, *therapy]; 8. *Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Self Care [*methods]; 11. Smoking Cessation; 12. Steroids [therapeutic use];
MESH terms:
ProSeal versus Classic laryngeal mask airway (LMA) for positive pressure ventilation in adults undergoing elective surgery
1. *Elective Surgical Procedures; 2. *Laryngeal Masks [adverse effects, classification]; 3. Oxygen Consumption; 4. Positive‐Pressure Respiration [*instrumentation]; 5. Randomized Controlled Trials as Topic; 6. Treatment Failure;
MESH terms:
Non‐invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease
1. Disease Progression; 2. Noninvasive Ventilation [*methods]; 3. Positive‐Pressure Respiration [*methods]; 4. Pulmonary Disease, Chronic Obstructive [*complications]; 5. Randomized Controlled Trials as Topic; 6. Respiratory Insufficiency [etiology, *therapy];
MESH terms:
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)
1. Anti-Bacterial Agents [therapeutic use]; 2. Bromides [adverse effects, *therapeutic use]; 3. Disease Progression; 4. Forced Expiratory Volume; 5. Hospitalization [statistics & numerical data]; 6. Numbers Needed To Treat; 7. Placebos [therapeutic use]; 8. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 9. Quality of Life; 10. Quinuclidines [adverse effects, *therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Smoking [epidemiology]; 13. Steroids [therapeutic use];
MESH terms:
Mass media interventions for preventing smoking in young people
1. Age Factors; 2. Case-Control Studies; 3. *Health Education; 4. Health Promotion; 5. Interrupted Time Series Analysis; 6. *Mass Media; 7. Smoking [epidemiology]; 8. *Smoking Prevention;
MESH terms:
Computer and mobile technology interventions for self‐management in chronic obstructive pulmonary disease
1. *Microcomputers; 2. *Mobile Applications; 3. *Smartphone; 4. Disease Progression; 5. Exercise; 6. Hospitalization [statistics & numerical data]; 7. Patient Education as Topic; 8. Pulmonary Disease, Chronic Obstructive [*therapy]; 9. Quality of Life; 10. Self Care [*methods]; 11. Smoking Cessation [statistics & numerical data]; 12. Therapy, Computer‐Assisted [*methods]; 13. Time Factors;
MESH terms:
Tobacco packaging design for reducing tobacco use
1. Prevalence; 2. Product Labeling [*methods, standards]; 3. Product Packaging [*methods, standards]; 4. Smoking [epidemiology]; 5. Smoking Cessation [statistics & numerical data]; 6. Smoking Prevention; 7. Tobacco Use [epidemiology, *prevention & control];
MESH terms:
Lay‐led and peer support interventions for adolescents with asthma
1. *Peer Influence; 2. *Self Care; 3. *Smoking Cessation; 4. *Social Support; 5. Asthma [*prevention & control]; 6. Disease Progression; 7. Medication Adherence [statistics & numerical data]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Smoking [adverse effects]; 11. Tobacco Use Disorder [epidemiology];
MESH terms:
Interventions to improve adherence to inhaled steroids for asthma
1. *Medication Adherence; 2. Administration, Inhalation; 3. Adrenal Cortex Hormones [administration & dosage]; 4. Anti‐Asthmatic Agents [*administration & dosage]; 5. Asthma [*drug therapy]; 6. Directly Observed Therapy; 7. Disease Progression; 8. Health Services Needs and Demand [statistics & numerical data]; 9. Patient Education as Topic; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Reminder Systems; 13. Steroids [*administration & dosage]; 14. Time Factors;
MESH terms:
Asthma education for school staff
1. *Program Evaluation; 2. *School Teachers; 3. *Schools; 4. *Teacher Training; 5. Absenteeism; 6. Asthma [*therapy]; 7. Emergency Service, Hospital [statistics & numerical data]; 8. Health Knowledge, Attitudes, Practice; 9. Quality of Life; 10. Randomized Controlled Trials as Topic;
MESH terms:
Group behaviour therapy programmes for smoking cessation
1. Behavior Therapy [*methods]; 2. Counseling; 3. Program Evaluation; 4. *Psychotherapy, Group; 5. Randomized Controlled Trials as Topic; 6. Self-Help Groups; 7. Smoking [drug therapy]; 8. Smoking Cessation [*methods, statistics & numerical data]; 9. *Smoking Prevention;
MESH terms:
Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease
1. Anxiety Disorders [*therapy]; 2. Bronchitis, Chronic [psychology]; 3. Emphysema [psychology]; 4. Exercise Tolerance; 5. Psychotherapy [*methods]; 6. Pulmonary Disease, Chronic Obstructive [*psychology]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 3. Anti‐Asthmatic Agents [*administration & dosage, adverse effects]; 4. Asthma [*drug therapy]; 5. Disease Progression; 6. Drug Therapy, Combination; 7. Forced Expiratory Volume [drug effects]; 8. Leukotriene Antagonists [*administration & dosage, adverse effects]; 9. Numbers Needed To Treat; 10. Peak Expiratory Flow Rate [drug effects]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Interventions to improve inhaler technique for people with asthma
1. *Administration, Inhalation; 2. Anti-Asthmatic Agents [*administration & dosage]; 3. Asthma [*drug therapy]; 4. Disease Progression; 5. *Nebulizers and Vaporizers; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
System change interventions for smoking cessation
1. *Organizational Policy; 2. Counseling [statistics & numerical data]; 3. Health Facilities; 4. Hotlines [statistics & numerical data]; 5. Organizational Innovation; 6. Randomized Controlled Trials as Topic; 7. Smoking [*therapy]; 8. Smoking Cessation [*methods, statistics & numerical data]; 9. Tobacco Use Cessation Devices; 10. Tobacco Use Disorder [diagnosis, *therapy];
MESH terms:
Fluid restriction for treatment of preterm infants with chronic lung disease
1. Apnea [epidemiology]; 2. Bronchopulmonary Dysplasia [*therapy]; 3. Chronic Disease; 4. Fluid Therapy [*methods]; 5. Infant, Premature; 6. Length of Stay [statistics & numerical data]; 7. Lung Diseases [therapy]; 8. Oxygen Inhalation Therapy; 9. Randomized Controlled Trials as Topic; 10. Respiration, Artificial [statistics & numerical data]; 11. Weight Gain;
MESH terms:
Stepping down the dose of inhaled corticosteroids for adults with asthma
1. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 2. Anti‐Asthmatic Agents [*administration & dosage, adverse effects]; 3. Asthma [*drug therapy]; 4. Forced Expiratory Volume; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
1. Cause of Death; 2. Community-Acquired Infections [prevention & control]; 3. Pneumococcal Infections [mortality, *prevention & control]; 4. Pneumococcal Vaccines [*administration & dosage]; 5. Pneumonia, Pneumococcal [prevention & control]; 6. Pulmonary Disease, Chronic Obstructive [*complications, mortality]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Combined inhaled beta‐agonist and anticholinergic agents for emergency management in adults with asthma
1. Adrenergic beta‐2 Receptor Agonists [*therapeutic use]; 2. Albuterol [therapeutic use]; 3. Anti‐Asthmatic Agents [*therapeutic use]; 4. Asthma [*drug therapy]; 5. Atropine [therapeutic use]; 6. Cholinergic Antagonists [*therapeutic use]; 7. Drug Therapy, Combination; 8. Forced Expiratory Volume [drug effects]; 9. Ipratropium [therapeutic use]; 10. Levalbuterol [therapeutic use]; 11. Metaproterenol [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Scopolamine Derivatives [therapeutic use];
MESH terms:
Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease
1. *Patient Education as Topic; 2. *Self Care; 3. Behavior Therapy; 4. Disease Progression; 5. Health Promotion; 6. Health Services Needs and Demand [statistics & numerical data]; 7. Hospitalization [statistics & numerical data]; 8. Patient Care Planning [*organization & administration]; 9. Pulmonary Disease, Chronic Obstructive [diagnosis, *therapy]; 10. Quality of Life; 11. Randomized Controlled Trials as Topic;
MESH terms:
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease
1. *Exercise Tolerance; 2. Disease Progression; 3. Health Status; 4. Hospitalization [*statistics & numerical data]; 5. Patient Readmission [statistics & numerical data]; 6. Pulmonary Disease, Chronic Obstructive [mortality, *rehabilitation]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Resistance Training [methods];
MESH terms:
Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
1. Dyspnea [etiology, *therapy]; 2. Exercise; 3. Health Status; 4. Home Care Services; 5. Oxygen Inhalation Therapy [*methods]; 6. Pulmonary Disease, Chronic Obstructive [complications, *therapy]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Upper limb exercise training for COPD
1. *Arm; 2. Dyspnea [etiology, *rehabilitation]; 3. Exercise Therapy [*methods]; 4. Muscle Strength; 5. Pulmonary Disease, Chronic Obstructive [complications, *rehabilitation]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Exhaled nitric oxide levels to guide treatment for children with asthma
1. Administration, Oral; 2. Adrenal Cortex Hormones [*administration & dosage]; 3. Anti-Asthmatic Agents [*administration & dosage]; 4. Asthma [*drug therapy]; 5. Breath Tests; 6. Disease Progression; 7. Exhalation; 8. Nitric Oxide [*analysis]; 9. Randomized Controlled Trials as Topic; 10. Spirometry;
MESH terms:
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
1. Bronchodilator Agents [*administration & dosage]; 2. Disease Progression; 3. *Dry Powder Inhalers; 4. Forced Expiratory Volume; 5. Inhalation Spacers [adverse effects]; 6. *Metered Dose Inhalers [adverse effects]; 7. Pulmonary Disease, Chronic Obstructive [*drug therapy, physiopathology]; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Smoking cessation for people with chronic obstructive pulmonary disease
1. Behavior Therapy [*methods]; 2. Bupropion [therapeutic use]; 3. Combined Modality Therapy [methods]; 4. Nicotine [therapeutic use]; 5. Nicotinic Agonists [*therapeutic use]; 6. *Pulmonary Disease, Chronic Obstructive; 7. Randomized Controlled Trials as Topic; 8. Smoking Cessation [*methods]; 9. Varenicline [therapeutic use];
MESH terms:
Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants
1. Bosentan; 2. Endothelin Receptor Antagonists [*therapeutic use]; 3. Extracorporeal Membrane Oxygenation; 4. Hypertension, Pulmonary [*drug therapy]; 5. Infant, Premature; 6. Nitrous Oxide [*therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Sulfonamides [*therapeutic use]; 9. Term Birth; 10. Treatment Failure;
MESH terms:
Home telemonitoring and remote feedback between clinic visits for asthma
1. Asthma [*diagnosis, drug therapy]; 2. *Feedback; 3. Internet; 4. Monitoring, Ambulatory [*methods]; 5. Randomized Controlled Trials as Topic; 6. Recurrence; 7. Secondary Prevention [methods]; 8. Self Care [*methods]; 9. Telephone; 10. Text Messaging;
MESH terms:
Guanylate cyclase stimulators for pulmonary hypertension
1. *Guanylate Cyclase; 2. Hypertension, Pulmonary [*drug therapy]; 3. Pyrazoles [*therapeutic use]; 4. Pyrimidines [*therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Time Factors; 7. Walking;
MESH terms:
Codeine versus placebo for chronic cough in children
1. Antitussive Agents [adverse effects, *therapeutic use]; 2. Chronic Disease; 3. Codeine [adverse effects, *therapeutic use]; 4. Cough [*drug therapy]; 5. Placebos [therapeutic use];
MESH terms:
Ambulatory and short‐burst oxygen for interstitial lung disease
1. Ambulatory Care [methods]; 2. Dyspnea [therapy]; 3. Exercise Tolerance; 4. Idiopathic Pulmonary Fibrosis [*therapy]; 5. Lung Diseases, Interstitial [*therapy]; 6. Oxygen Inhalation Therapy [*methods]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
1. Administration, Inhalation; 2. Adrenergic beta‐2 Receptor Agonists [*administration & dosage]; 3. Bronchodilator Agents [*administration & dosage]; 4. Drug Therapy, Combination [methods]; 5. Glucocorticoids [*administration & dosage]; 6. Pulmonary Disease, Chronic Obstructive [*drug therapy, mortality]; 7. Randomized Controlled Trials as Topic; 8. Tiotropium Bromide [*administration & dosage];
MESH terms:
Different oral corticosteroid regimens for acute asthma
1. Acute Disease; 2. Administration, Oral; 3. Adrenal Cortex Hormones; 4. Anti‐Asthmatic Agents [*administration & dosage]; 5. Asthma [*drug therapy]; 6. Dexamethasone [*administration & dosage]; 7. Glucocorticoids [*administration & dosage]; 8. Hospitalization; 9. Prednisolone [*administration & dosage]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Intravenous magnesium sulfate for treating children with acute asthma in the emergency department
1. *Emergency Service, Hospital; 2. Acute Disease; 3. Anti‐Asthmatic Agents [*administration & dosage]; 4. Asthma [*drug therapy]; 5. Hospitalization; 6. Injections, Intravenous; 7. Magnesium Sulfate [*administration & dosage];
MESH terms:
Remote versus face‐to‐face check‐ups for asthma
1. Administration, Oral; 2. Adrenal Cortex Hormones [*administration & dosage]; 3. Anti-Asthmatic Agents [*administration & dosage]; 4. Asthma [*diagnosis, *drug therapy]; 5. Disease Progression; 6. Internet; 7. Office Visits; 8. Randomized Controlled Trials as Topic; 9. Remote Consultation [*methods]; 10. Telephone;
MESH terms:
Breathing exercises for children with asthma
1. *Breathing Exercises; 2. Anti‐Asthmatic Agents [therapeutic use]; 3. Asthma [*drug therapy, physiopathology]; 4. Lung [physiopathology]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
High‐frequency oscillatory ventilation versus conventional ventilation for acute respiratory distress syndrome
1. Acute Lung Injury [mortality, *therapy]; 2. High‐Frequency Ventilation [*methods, mortality]; 3. Hospital Mortality; 4. Randomized Controlled Trials as Topic; 5. Respiration, Artificial [*methods, mortality]; 6. Respiratory Distress Syndrome [mortality, *therapy]; 7. Time Factors;
MESH terms:
Combined pharmacotherapy and behavioural interventions for smoking cessation
1. Behavior Therapy [*methods]; 2. Combined Modality Therapy [methods]; 3. Counseling [methods]; 4. Randomized Controlled Trials as Topic; 5. Smoking [*therapy]; 6. Smoking Cessation [*methods]; 7. Tobacco Use Cessation Devices;
MESH terms:
Protocolized versus non‐protocolized weaning for reducing the duration of invasive mechanical ventilation in newborn infants
1. *Clinical Protocols; 2. Intensive Care Units, Neonatal; 3. Length of Stay; 4. Respiration, Artificial [*adverse effects]; 5. Respiratory Insufficiency [*therapy]; 6. Time Factors; 7. Ventilator Weaning [*methods];
MESH terms:
Smoking cessation advice for people with serious mental illness
1. *Counseling; 2. *Mental Disorders; 3. *Smoking Cessation;
MESH terms:
Inhaled non‐steroid anti‐inflammatories for children and adults with bronchiectasis
1. Administration, Inhalation; 2. Anti‐Inflammatory Agents, Non‐Steroidal [*administration & dosage]; 3. Bronchiectasis [*drug therapy]; 4. Dyspnea [drug therapy]; 5. Sputum [metabolism];
MESH terms:
Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta2‐agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*therapeutic use]; 3. Adrenergic beta‐2 Receptor Agonists [*therapeutic use]; 4. Asthma [*drug therapy]; 5. Disease Progression; 6. Drug Therapy, Combination [methods]; 7. Muscarinic Antagonists [adverse effects, *therapeutic use]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Tiotropium Bromide [adverse effects, *therapeutic use];
MESH terms:
Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants
1. Cattle; 2. Infant, Premature; 3. Oxygen Inhalation Therapy; 4. Pulmonary Surfactants [*therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Respiratory Distress Syndrome, Newborn [*drug therapy, mortality]; 7. Swine;
MESH terms:
Addition of long‐acting beta2‐agonists to inhaled corticosteroids for chronic asthma in children
1. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 2. Adrenergic beta‐Agonists [*administration & dosage, adverse effects]; 3. Albuterol [administration & dosage, analogs & derivatives]; 4. Anti‐Asthmatic Agents [*administration & dosage, adverse effects]; 5. Asthma [*drug therapy]; 6. Beclomethasone [administration & dosage, adverse effects]; 7. Chronic Disease; 8. Disease Progression; 9. Drug Therapy, Combination; 10. Ethanolamines [administration & dosage]; 11. Formoterol Fumarate [administration & dosage, adverse effects]; 12. Randomized Controlled Trials as Topic; 13. Salmeterol Xinafoate [administration & dosage, adverse effects];
MESH terms:
Airway clearance techniques for bronchiectasis
1. Bronchiectasis [complications, *therapy]; 2. Chest Wall Oscillation [instrumentation]; 3. Cough; 4. Disease Progression; 5. Drainage, Postural; 6. Health Status; 7. Hospitalization [statistics & numerical data]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Respiratory Therapy [*methods]; 11. Sputum [*metabolism];
MESH terms:
Interventions for enhancing adherence to treatment in adults with bronchiectasis
1. Bronchiectasis [*therapy]; 2. Patient Compliance [*psychology];
MESH terms:
Exercise training to improve exercise capacity and quality of life in people with non‐malignant dust‐related respiratory diseases
1. *Exercise Tolerance; 2. *Quality of Life; 3. Asbestosis [rehabilitation]; 4. Dust; 5. Health Status; 6. Physical Conditioning, Human [*methods]; 7. Pneumoconiosis [*rehabilitation]; 8. Randomized Controlled Trials as Topic; 9. Respiration Disorders [*rehabilitation]; 10. Time Factors;
MESH terms:
Interventions for smokeless tobacco use cessation
1. *Tobacco, Smokeless; 2. Benzazepines [therapeutic use]; 3. Bupropion [therapeutic use]; 4. Chewing Gum; 5. Counseling; 6. Nicotine [therapeutic use]; 7. Nicotinic Agonists [therapeutic use]; 8. Quinoxalines [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Tobacco Use Cessation [*methods]; 11. Varenicline [therapeutic use];
MESH terms:
Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease
1. Adrenergic beta‐2 Receptor Agonists [*therapeutic use]; 2. Albuterol [analogs & derivatives, therapeutic use]; 3. Bronchodilator Agents [*therapeutic use]; 4. Ethanolamines [therapeutic use]; 5. Formoterol Fumarate [therapeutic use]; 6. Indans [therapeutic use]; 7. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 8. Quality of Life; 9. Quinolones [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Salmeterol Xinafoate [therapeutic use]; 12. Scopolamine Derivatives [therapeutic use]; 13. Tiotropium Bromide [*therapeutic use];
MESH terms:
Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children
1. Acetates [*therapeutic use]; 2. Common Cold [complications, virology]; 3. Cyclopropanes; 4. Leukotriene Antagonists [*therapeutic use]; 5. Maintenance Chemotherapy [methods]; 6. Quinolines [*therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Respiratory Sounds [*drug effects]; 9. Respiratory Tract Infections [*complications]; 10. Sulfides; 11. Time Factors; 12. Virus Diseases [*complications];
MESH terms:
Tonsillectomy or adenotonsillectomy versus non‐surgical management for obstructive sleep‐disordered breathing in children
1. Adenoidectomy [adverse effects, *methods]; 2. Randomized Controlled Trials as Topic; 3. Sleep Apnea, Obstructive [*surgery]; 4. Tonsillectomy [adverse effects, *methods];
MESH terms:
Calcium channel blockers for pulmonary arterial hypertension
1. Benzimidazoles [therapeutic use]; 2. Benzoates [therapeutic use]; 3. Calcium Channel Blockers [*therapeutic use]; 4. Hypertension, Pulmonary [*drug therapy]; 5. Nifedipine [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Telmisartan;
MESH terms:
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease
1. Bronchodilator Agents [adverse effects, *therapeutic use]; 2. Forced Expiratory Volume; 3. Ipratropium [adverse effects, *therapeutic use]; 4. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Scopolamine Derivatives [adverse effects, *therapeutic use]; 7. Tiotropium Bromide [adverse effects, *therapeutic use];
MESH terms:
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 3. Anti‐Asthmatic Agents [*administration & dosage, adverse effects]; 4. Asthma [*drug therapy]; 5. Disease Progression; 6. Drug Therapy, Combination [methods]; 7. Muscarinic Antagonists [*administration & dosage, adverse effects]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome
1. Cerebral Hemorrhage [chemically induced]; 2. Drug Combinations; 3. Enterocolitis, Necrotizing [chemically induced]; 4. Fatty Alcohols [therapeutic use]; 5. Infant, Premature; 6. Polyethylene Glycols [therapeutic use]; 7. Pulmonary Surfactants [adverse effects, *therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Respiratory Distress Syndrome, Newborn [*drug therapy, *prevention & control];
MESH terms:
Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults
1. Anti‐Bacterial Agents [*administration & dosage, adverse effects]; 2. Bronchiectasis [*drug therapy, microbiology]; 3. Diarrhea [chemically induced]; 4. Disease Progression; 5. Drug Resistance, Bacterial; 6. Hospitalization [statistics & numerical data]; 7. Odds Ratio; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults
1. Administration, Inhalation; 2. Administration, Oral; 3. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 4. Anti‐Asthmatic Agents [*administration & dosage, adverse effects]; 5. Asthma [*drug therapy]; 6. Disease Progression; 7. Randomized Controlled Trials as Topic;
MESH terms:
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*administration & dosage]; 3. Anti‐Asthmatic Agents [administration & dosage]; 4. Asthma [*drug therapy]; 5. Beclomethasone [administration & dosage]; 6. Cross‐Over Studies; 7. Muscarinic Antagonists [*administration & dosage]; 8. Randomized Controlled Trials as Topic; 9. Tiotropium Bromide [administration & dosage];
MESH terms:
Effects of opioid, hypnotic and sedating medications on sleep‐disordered breathing in adults with obstructive sleep apnoea
1. Analgesics, Opioid [administration & dosage, *adverse effects]; 2. Apnea [chemically induced, diagnosis]; 3. Benzodiazepines [administration & dosage, adverse effects]; 4. Disease Progression; 5. Hypnotics and Sedatives [administration & dosage, *adverse effects]; 6. Oxygen Consumption [drug effects]; 7. Randomized Controlled Trials as Topic; 8. Sleep Apnea, Obstructive [*chemically induced];
MESH terms:
Stopping long‐acting beta2‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
1. *Withholding Treatment; 2. Administration, Inhalation; 3. Adrenal Cortex Hormones [administration & dosage]; 4. Adrenergic beta‐2 Receptor Agonists [*administration & dosage]; 5. Anti‐Asthmatic Agents [*administration & dosage]; 6. Asthma [*drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Time Factors;
MESH terms:
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*administration & dosage]; 3. Adrenergic beta‐2 Receptor Agonists [*administration & dosage]; 4. Asthma [*drug therapy]; 5. Double‐Blind Method; 6. Drug Therapy, Combination [methods]; 7. Muscarinic Antagonists [*administration & dosage]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Salmeterol Xinafoate [administration & dosage]; 11. Tiotropium Bromide [administration & dosage];
MESH terms:
Stopping long‐acting beta2‐agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids
1. *Withholding Treatment; 2. Administration, Inhalation; 3. Adrenal Cortex Hormones [*administration & dosage]; 4. Adrenergic beta‐2 Receptor Agonists [*administration & dosage]; 5. Asthma [*drug therapy];
MESH terms:
Pulmonary rehabilitation for chronic obstructive pulmonary disease
1. *Exercise Tolerance; 2. *Health Status; 3. *Quality of Life; 4. Dyspnea [rehabilitation]; 5. Pulmonary Disease, Chronic Obstructive [psychology, *rehabilitation]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Pressure‐controlled versus volume‐controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS)
1. Acute Lung Injury [*complications, mortality]; 2. Critical Care; 3. Hospital Mortality; 4. Pressure; 5. Randomized Controlled Trials as Topic; 6. Respiration, Artificial [adverse effects, *methods, mortality]; 7. Respiratory Distress Syndrome [*complications, mortality]; 8. Respiratory Insufficiency [etiology, mortality, *therapy]; 9. Selection Bias;
MESH terms:
Early versus late tracheostomy for critically ill patients
1. Critical Care [*methods]; 2. Critical Illness [mortality, *therapy]; 3. Length of Stay [statistics & numerical data]; 4. Pneumonia [mortality]; 5. Randomized Controlled Trials as Topic; 6. Respiration, Artificial [statistics & numerical data]; 7. Time Factors; 8. Tracheostomy [adverse effects, *methods, mortality];
MESH terms:
Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
1. Adrenergic beta‐2 Receptor Agonists [*administration & dosage]; 2. Drug Administration Schedule; 3. Forced Expiratory Volume [physiology]; 4. Formoterol Fumarate [administration & dosage]; 5. Indans [*administration & dosage]; 6. Pulmonary Disease, Chronic Obstructive [drug therapy]; 7. Quinolones [*administration & dosage]; 8. Randomized Controlled Trials as Topic; 9. Salmeterol Xinafoate [administration & dosage];
MESH terms:
Alpha‐2 agonists for long‐term sedation during mechanical ventilation in critically ill patients
1. *Critical Illness; 2. Adrenergic alpha‐2 Receptor Agonists [adverse effects, *therapeutic use]; 3. Bradycardia [chemically induced]; 4. Clonidine [therapeutic use]; 5. Conscious Sedation [*methods]; 6. Dexmedetomidine [adverse effects, *therapeutic use]; 7. Lorazepam [adverse effects, therapeutic use]; 8. Midazolam [adverse effects, therapeutic use]; 9. Propofol [adverse effects, therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Respiration, Artificial [*statistics & numerical data]; 12. Selection Bias; 13. Time Factors;
MESH terms:
Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants
1. Bronchopulmonary Dysplasia [mortality, *prevention & control]; 2. Gestational Age; 3. Infant, Premature; 4. Infant, Premature, Diseases [mortality, *prevention & control]; 5. Pentoxifylline [*therapeutic use]; 6. Phosphodiesterase Inhibitors [*therapeutic use]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Aclidinium bromide for stable chronic obstructive pulmonary disease
1. Adrenergic beta‐2 Receptor Agonists [therapeutic use]; 2. Bronchodilator Agents [*therapeutic use]; 3. Disease Progression; 4. Muscarinic Antagonists [*therapeutic use]; 5. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 6. Randomized Controlled Trials as Topic; 7. Scopolamine Derivatives [therapeutic use]; 8. Tiotropium Bromide; 9. Tropanes [*therapeutic use];
MESH terms:
Automated weaning and SBT systems versus non‐automated weaning strategies for weaning time in invasively ventilated critically ill adults
1. *Critical Illness; 2. *Ventilators, Mechanical [adverse effects]; 3. Automation [*instrumentation]; 4. Intensive Care Units; 5. Length of Stay; 6. Randomized Controlled Trials as Topic; 7. Time Factors; 8. Ventilator Weaning [*instrumentation, *methods]; 9. Work of Breathing;
MESH terms:
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
1. Acute Disease; 2. Administration, Oral; 3. Disease Progression; 4. Glucocorticoids [*administration & dosage, adverse effects]; 5. Infusions, Intravenous; 6. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Continuous positive airway pressure (CPAP) during the postoperative period for prevention of postoperative morbidity and mortality following major abdominal surgery
1. *Continuous Positive Airway Pressure; 2. Abdomen [*surgery]; 3. Cause of Death; 4. Hypoxia [prevention & control]; 5. Intensive Care Units; 6. Laparotomy; 7. Length of Stay; 8. Pneumonia [*prevention & control]; 9. Postoperative Complications [mortality, *prevention & control]; 10. Postoperative Period; 11. Pulmonary Atelectasis [*prevention & control]; 12. Randomized Controlled Trials as Topic; 13. Retreatment [statistics & numerical data];
MESH terms:
Inhaled anticholinergics and short‐acting beta2‐agonists versus short‐acting beta2‐agonists alone for children with acute asthma in hospital
1. Acute Disease; 2. Administration, Inhalation; 3. Adrenergic beta‐2 Receptor Agonists [*administration & dosage]; 4. Anti‐Asthmatic Agents [*administration & dosage]; 5. Asthma [*drug therapy]; 6. Cholinergic Antagonists [*administration & dosage]; 7. Drug Administration Schedule; 8. Drug Therapy, Combination; 9. Hospitalization; 10. Ipratropium [administration & dosage]; 11. Nebulizers and Vaporizers; 12. Randomized Controlled Trials as Topic;
MESH terms:
Tiotropium versus placebo for chronic obstructive pulmonary disease
1. Bronchodilator Agents [*therapeutic use]; 2. Cholinergic Antagonists [*therapeutic use]; 3. Disease Progression; 4. Dry Powder Inhalers; 5. Nebulizers and Vaporizers; 6. Placebo Effect; 7. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Scopolamine Derivatives [*therapeutic use]; 11. Tiotropium Bromide;
MESH terms:
Water‐based exercise for adults with asthma
1. *Gymnastics; 2. *Swimming; 3. *Water; 4. Anti‐Asthmatic Agents [therapeutic use]; 5. Asthma [*therapy]; 6. Randomized Controlled Trials as Topic; 7. Resistance Training [*methods];
MESH terms:
Inhaled corticosteroids in children with persistent asthma: effects on growth
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [administration & dosage, *adverse effects]; 3. Androstadienes [administration & dosage, adverse effects]; 4. Anti‐Asthmatic Agents [administration & dosage, *adverse effects]; 5. Asthma [*drug therapy]; 6. Beclomethasone [administration & dosage, adverse effects]; 7. Budesonide [administration & dosage, adverse effects]; 8. Fluocinolone Acetonide [administration & dosage, adverse effects, analogs & derivatives]; 9. Fluticasone; 10. Growth [*drug effects]; 11. Growth Disorders [*chemically induced]; 12. Mometasone Furoate; 13. Patient Dropouts [statistics & numerical data]; 14. Pregnadienediols [administration & dosage, adverse effects]; 15. Pregnenediones [administration & dosage, adverse effects];
MESH terms:
Inhaled corticosteroids in children with persistent asthma: dose‐response effects on growth
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 3. Androstadienes [administration & dosage, adverse effects]; 4. Anti‐Asthmatic Agents [*administration & dosage, adverse effects]; 5. Asthma [*drug therapy]; 6. Beclomethasone [administration & dosage, adverse effects]; 7. Budesonide [administration & dosage, adverse effects]; 8. Dose‐Response Relationship, Drug; 9. Fluticasone; 10. Growth [*drug effects]; 11. Growth Disorders [*chemically induced]; 12. Mometasone Furoate; 13. Pregnadienediols [administration & dosage, adverse effects]; 14. Pregnenediones [administration & dosage, adverse effects]; 15. Randomized Controlled Trials as Topic;
MESH terms:
Ambulatory oxygen for people with chronic obstructive pulmonary disease who are not hypoxaemic at rest
1. Ambulatory Care; 2. Exercise [physiology]; 3. Hypoxia [therapy]; 4. Oxygen Inhalation Therapy [*methods]; 5. Pulmonary Disease, Chronic Obstructive [blood, physiopathology, *therapy]; 6. Randomized Controlled Trials as Topic; 7. Rest;
MESH terms:
Combination inhaled corticosteroids and long‐acting beta2‐agonists for children and adults with bronchiectasis
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*administration & dosage]; 3. Adrenergic beta‐2 Receptor Agonists [*administration & dosage]; 4. Bronchiectasis [*drug therapy]; 5. Budesonide [administration & dosage]; 6. Disease Progression; 7. Drug Therapy, Combination [methods]; 8. Ethanolamines [administration & dosage]; 9. Formoterol Fumarate; 10. Randomized Controlled Trials as Topic;
MESH terms:
Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
1. *Emergency Service, Hospital; 2. Anti‐Asthmatic Agents [*administration & dosage, adverse effects]; 3. Asthma [*drug therapy]; 4. Hospitalization [statistics & numerical data]; 5. Infusions, Intravenous [methods]; 6. Magnesium Sulfate [*administration & dosage, adverse effects]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Written emotional disclosure for asthma
1. *Disclosure; 2. *Writing; 3. Asthma [*psychology, therapy]; 4. Forced Expiratory Volume; 5. Psychotherapy [*methods]; 6. Randomized Controlled Trials as Topic; 7. Stress, Psychological [*therapy];
MESH terms:
Non‐invasive ventilation during exercise training for people with chronic obstructive pulmonary disease
1. *Noninvasive Ventilation; 2. Exercise Tolerance [*physiology]; 3. Forced Expiratory Volume [physiology]; 4. Physical Conditioning, Human [*methods, physiology]; 5. Pulmonary Disease, Chronic Obstructive [physiopathology, *rehabilitation]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Mucolytics for bronchiectasis
1. Anti‐Bacterial Agents [therapeutic use]; 2. Bromhexine [therapeutic use]; 3. Bronchiectasis [*therapy]; 4. Deoxyribonucleases [therapeutic use]; 5. Drug Therapy, Combination; 6. Expectorants [*therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Recombinant Proteins [therapeutic use]; 9. Thioglycolates [therapeutic use]; 10. Thiophenes [therapeutic use];